Long-term Treatment With Luspatercept Reduces Transfusion Dependence Associated With β-Thalassemia - OncLive
6/12/2022 12:00:00 AM2 years 10 months ago
by Brittany Lovely
by Brittany Lovely
The longest duration of reduction in red blood cell transfusion dependence was reported among patients with β-thalassemia who received continued treatment with luspatercept-aamt in the updated data from the phase 3 BELIEVE trial.
The longest duration of reduction in red blood cell (RBC) transfusion dependence was reported among patients with -thalassemia who received continued treatment with luspatercept-aamt (Reblozyl) in th… [+7309 chars]
full article...